Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Levengood, M.R.; van der Donk, W.A.
    Use of lantibiotic synthetases for the preparation of bioactive constrained peptides (2008), Bioorg. Med. Chem. Lett., 18, 3025-3028.
    View publication on PubMedView publication on EuropePMC

Inhibitors

EC Number Inhibitors Comment Organism Structure
3.4.11.4 2,5-diamino-8-carbamimidamido-N-(4,8-diamino-5-methyl-1-methylidene-2,3,7-trioxononyl)-4-oxooctanamide potent inhibitor Homo sapiens
3.4.14.10 N-[[(L-arginyl-L-alanyl)amino](oxo)acetyl]-L-valyl-L-alanine potent inhibitor Homo sapiens

Localization

EC Number Localization Comment Organism GeneOntology No. Textmining
3.4.14.10 cytosol
-
 Homo sapiens 5829
-

Organism

EC Number Organism UniProt Comment Textmining
3.4.11.4 Homo sapiens
-
-
-
3.4.14.10 Homo sapiens
-
-
-

Source Tissue

EC Number Source Tissue Comment Organism Textmining
3.4.11.4 erythrocyte
-
 Homo sapiens
-
3.4.14.10 erythrocyte
-
 Homo sapiens
-

Synonyms

EC Number Synonyms Comment Organism
3.4.11.4 tripeptidyl exopeptidase II
-
 Homo sapiens
3.4.14.10 TPII
-
 Homo sapiens
3.4.14.10 tripeptidyl peptidase II
-
 Homo sapiens

Ki Value [mM]

EC Number Ki Value [mM] Ki Value maximum [mM] Inhibitor Comment Organism Structure
3.4.11.4 0.00002
-
 2,5-diamino-8-carbamimidamido-N-(4,8-diamino-5-methyl-1-methylidene-2,3,7-trioxononyl)-4-oxooctanamide
-
 Homo sapiens